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Recent iPrEx clinical trial results provided evidence that systemic preexposure prophylaxis (PrEP) with emtric-
itabine (FTC) and tenofovir disoproxil fumarate (TDF) can partially prevent rectal HIV transmission in humans.
Similarly, we have previously demonstrated that systemic administration of the same FTC-TDF combination
efficiently prevented rectal transmission in humanized bone marrow/liver/thymus (BLT) mice. The CAPRISA 004
trial recently demonstrated that topical application of the tenofovir could partially prevent vaginal HIV-1 trans-
mission in humans. To further validate the usefulness of the BLT mouse model for testing HIV prevention
strategies, we evaluated the topical administration of tenofovir as used in CAPRISA 004 to prevent vaginal HIV
transmission in BLT mice. Our results demonstrate that vaginally administered 1% tenofovir significantly reduced
HIV transmission in BLT mice (P  0.002). Together with the results obtained after systemic antiretroviral PrEP,
these topical inhibitor data serve to validate the use of humanized BLT mice to evaluate both systemic and topical
inhibitors of HIV transmission. Based on these observations, we tested six additional microbicide candidates for
their ability to prevent vaginal HIV transmission: a C-peptide fusion inhibitor (C52L), a membrane-disrupting
amphipathic peptide inhibitor (C5A), a trimeric D-peptide fusion inhibitor (PIE12-Trimer), a combination of
reverse transcriptase inhibitors (FTC-TDF), a thioester zinc finger inhibitor (TC247), and a small-molecule Rac
inhibitor (NSC23766). No protection was seen with the Rac inhibitor NSC23766. The thioester compound TC247
offered partial protection. Significant protection was afforded by FTC-TDF, and complete protection was offered by
three different peptide inhibitors tested. Our results demonstrate that these effective topical inhibitors have excellent
potential to prevent vaginal HIV transmission in humans.
The continuous spread of the AIDS epidemic, with over 2.7
million new human immunodeficiency virus (HIV) infections
per year, highlights the need for successful prevention ap-
proaches (55). Proposed interventions to block HIV transmis-
sions include condoms, circumcision, vaccines, test-and-treat
strategies, systemic preexposure prophylaxis (PrEP), and top-
ical microbicides (7, 9, 13, 26, 30). Microbicides are products
that, when used vaginally or rectally, could result in protection
from HIV transmission. Several first-generation microbi-
cides with well-documented in vitro antiviral activity have
been tested in large clinical trials. Unfortunately, none of
these agents was found to be effective in preventing HIV-1
transmission in humans (14, 19, 44, 47).
The second generation of microbicide candidates focuses on
antiretrovirals (ARVs) that specifically target key aspects of
HIV replication such as fusion, viral entry, and reverse tran-
scription. However, only reverse transcriptase inhibitors that
are already routinely used to treat HIV-infected patients are
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currently undergoing large-scale clinical trials for efficacy in
HIV prevention (7, 9). One of these trials, the Center for the
AIDS Program of Research in South Africa (CAPRISA) 004,
recently reported that 1% tenofovir gel can partially prevent
vaginal HIV transmission (1). Likewise, the Preexposure Pro-
phylaxis Initiative (iPrEx) clinical trial recently reported that
oral administration of a combination of the reverse transcrip-
tase inhibitors emtricitabine (FTC) and tenofovir disoproxil
fumarate (TDF) provided partial protection from rectal HIV
transmission (18). If other active clinical trials also find reverse
transcriptase inhibitor-based PrEP to be successful, these
antiretrovirals might become extensively used as topical mi-
crobicides to prevent HIV transmission. However, there is
significant concern that viruses resistant to these drugs
could potentially emerge and spread, severely limiting avail-
able treatment options (26).
To preserve the integrity of frontline therapeutic ARV reg-
imens, there is strong interest in the development of novel
microbicides with resistance profiles that do not overlap with
those used for therapy. The evaluation of microbicide candi-
dates would benefit significantly from validated animal models
capable of accurately predicting human outcomes. Prior to the
completion of the iPrEx trial, we reported the efficacy of sys-
temic FTC-TDF to prevent vaginal and rectal HIV transmis-
sion in humanized bone marrow/liver/thymus (BLT) mice (11,
12). Systemic FTC-TDF also was reported to prevent rectal
simian-human immunodeficiency virus (SHIV) transmission in
rhesus macaques (17). As indicated above, this same combina-
tion of drugs was shown to also reduce the incidence of HIV
infection in humans (18). To further validate the utility of the
humanized BLT mouse model for the evaluation of HIV pre-
vention strategies, we evaluated the topical administration of
tenofovir as used in CAPRISA 004 (1) to prevent vaginal HIV
transmission in BLT mice. As in humans, our results demon-
strate that vaginally administered 1% tenofovir reduced HIV
transmission in BLT mice, highlighting the usefulness of this
model for the in vivo evaluation of HIV prevention interven-
tions. Based on these results, we extended our analysis and
tested the ability of six additional candidate microbicides with
distinct antiretroviral mechanisms of action (Table 1) to block
vaginal HIV transmission in the BLT model. In addition to
tenofovir, our comprehensive preclinical efficacy screen of
these six additional inhibitors identified four inhibitors with
strong protective capacity and substantial potential to prevent
HIV transmission in humans.
MATERIALS AND METHODS
Generation of humanized BLT mice. BLT mice were prepared essentially as
previously described (6, 11, 12, 24, 25, 31, 41, 45). Briefly, thymus/liver-implanted
NOD/SCID or NOD/SCID-gamma chain null mice (NSG) (The Jackson Labo-
ratories) were transplanted with autologous human fetal liver CD34 cells (Ad-
vanced Bioscience Resources) and monitored for human reconstitution in pe-
ripheral blood by flow cytometry, as we have previously described (11, 12, 31, 45).
Mice were maintained either at the Animal Resources Center of UT Southwest-
ern Medical Center at Dallas or with the Division of Laboratory Animal Med-
icine at the University of North Carolina (UNC) at Chapel Hill in accordance
with protocols approved by the each institution’s Institutional Animal Care and
Use Committee.
Topical administration of HIV inhibitors to BLT mice. Each inhibitor (20 l)
was applied vaginally within 30 min of vaginal viral exposure, except for the
vaginal application of 1% tenofovir [PMPA; 9-R-(2-phosphonomethoxypropyl)
adenine]. The 1% tenofovir was applied 4 h before and 4 h after vaginal viral
exposure in order to ensure full compliance with the CAPRISA 004 protocol,
which requires two applications of the inhibitor (one before and one after sex)
within a 24-h period (1). C52L peptide, a C-peptide fusion inhibitor, was pro-
duced and purified as previously described and applied at a working concentra-
tion of 500 M (10). C5A peptide, a membrane-disrupting amphipathic peptide
inhibitor, was produced and purified as previously described and applied at a
working concentration of 200 M (5). A trimeric D-peptide fusion inhibitor,
PIE12-Trimer, was produced and purified as previously described and applied at
a working concentration of 100 M (54). FTC-TDF was prepared as previously
published and applied at a working concentration of 28 M and 16.5 M,
respectively (12). Thioester compound 247 (TC247) was produced and purified
as previously described and applied at a working concentration of 500 M (32).
NSC23766 (Calbiochem), a small-molecule Rac inhibitor, was applied at a work-
ing concentration of 10 mM.
Exposure of BLT mice to HIV-1. Stocks of HIV-1JR-CSF were prepared, and
titers and p24 content were determined as we have previously described (53).
HIV-1 exposures were performed essentially as previously described using a total
volume of 2 to 10 l (170 ng p24) (11, 57).
Analysis of HIV-1 infection of BLT mice. Infection of BLT mice with HIV-1
was monitored in peripheral blood as follows: by determining plasma levels of
viral antigenemia using a p24 enzyme-linked immunosorbent assay ([ELISA]
assay sensitivity, 7.8 pg/ml; Coulter); by determining levels of viral RNA in
plasma using either an Amplicor (Roche) assay or one-step reverse transcriptase
real-time PCR (ABI custom TaqMan Assays-by-Design) according to the
manufacturer’s instructions (with primers 5-CATGTTTTCAGCATTATCA
GAAGGA-3 and 5-TGCTTGATGTCCCCCCACT-3 and MGB-probe 5-
FAM-CCACCCCACAAGATTTAAACACCATGCTAA-Q-3, where FAM
is 6-carboxyfluorescein [37]; assay sensitivity of 400 RNA copies per ml in both
assays); and by determining levels of viral DNA in peripheral blood cells (real-
time PCR analysis; assay sensitivity of 10 copies) as previously described (11, 12,
45, 53). The single-cell suspension preparation from the female reproductive
tract (FRT) was adapted from a published protocol (22). Briefly, the entire FRT
(vagina, cervix, uterus, fallopian tubes, and ovaries) was minced and then placed
in a 50-ml conical tube with 2 ml of fresh FRT digestion medium (25 units of
DNase I [Roche] plus 2 mg of collagenase D [Roche] in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine serum [FBS]). The samples
were shaken gently at room temperature for 2 h. Following this incubation, each
sample received an addition of 2 ml of EDTA medium (Ca2- and Mg2-free
Hanks buffered salt solution supplemented with 5% heat inactivated FBS and 5
mM EDTA) and was shaken gently at room temperature for 20 more minutes.
The samples were vortexed briefly and then filtered through a 70-m-pore-size
cell strainer. Cells were washed, counted using trypan blue exclusion, and utilized
as indicated throughout the text, on figures, and in tables. Other tissues were
harvested and then evaluated by molecular, microscopic, and flow cytometric
analyses for evidence of HIV infection as we have previously described (11, 12,
31, 45). The flow cytometry antibody panels for analysis of BLT mouse FRT were
TABLE 1. Inhibitors evaluated for efficacy in preventing vaginal HIV-1 transmission
Inhibitor Inhibitor category Mechanism of inhibition Concn applied (in 20 l)
Tenofovir Reverse transcriptase inhibitor Blocks reverse transcription 1% (34.8 mM)
C52L Peptide fusion inhibitor Blocks virus-cell fusion 500 M
C5A Peptide membrane disruptor Disrupts viral membrane prior to cell contact 200 M
PIE12-Trimer Peptide fusion inhibitor Blocks virus-cell fusion 100 M
FTC-TDF Reverse transcriptase inhibitors Blocks reverse transcription 28 M/16.5 M
TC247 Zinc finger inhibitor Blocks viral spreading 500 M
NSC23766 Rac inhibitor Blocks entry 10 mM
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the following: panel A, CD8 fluorescein isothiocyanate (FITC) (SK1), CXCR4
phycoerythrin (PE) (12G5) or IgG2ak PE (G155-178), CD4 peridinin chloro-
phyll protein (PerCP) (SK3), CD3 PE-Cy7 (SK7), CCR5 allophycocyanin (APC)
(3A9) or IgG2ak APC (G155-178), and CD45 APC-Cy7 (2D1); panel B, CD3
FITC (HIT3a), CD4 PE (RPA-T4), CD8 PerCP (SK1), and CD45 APC (HI30)
(all purchased from BD Biosciences).
Analysis of systemic infection was performed on tissues harvested from in-
fected mice or on cells isolated from the tissues indicated throughout the text, on
figures, and in tables. Utilizing in situ hybridization, real-time PCR analysis, and
coculture with allogeneic human peripheral blood mononuclear cells (PBMC) as
previously described (11, 12, 31, 45). An immunofluorescence assay was per-
formed on paraffin-embedded BLT FRT sections. After rehydration, antigen
retrieval was performed using 1 Diva Decloaker solution (Biocare Medical);
slides were cooled for 30 min, blocked with 2% normal donkey serum and 2%
Sniper blocking reagent in TNB (0.1 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.5%
blocking reagent [NEN]), and incubated at 4°C overnight with rabbit monoclonal
anti-human CD3 (Labvision), mouse anti-human CD11c (Novocastra), or mouse
anti-CD68 (Dako). After slides were washed, sections were incubated with the
following secondary antibodies: donkey anti-mouse IgG Alexa Fluor-488, donkey
anti-rabbit IgG Alexa Fluor-555, and 4,6-diamidino-2-phenylindole ([DAPI],
300 nM final concentration) (all from Molecular Probes) for 1 h at room tem-
perature. Sections were mounted in Aquapolymount (Polysciences, Inc.) and
imaged using a Nikon 80i fluorescent microscope using the 20 objective. Im-
ages were processed with Adobe Photoshop software, version CS3.
Statistics. All statistical analyses (alpha level, 0.05) were performed in Prism,
version 4 (Graph Pad). The box plot should be interpreted as follows: the middle
line is the median, the box extends from the 25th to the 75th percentiles, and the
error bars extend from lowest to highest values.
RESULTS
Our goal was to validate and implement a preclinical in vivo
experimental system to evaluate the ability of topically applied
inhibitors to prevent vaginal HIV-1 transmission. We first used
flow cytometry to characterize the site of exposure (i.e., the
female reproductive tract [FRT]) in BLT mice for the presence
of human CD4 CCR5 and CD8 CCR5 T cells (Fig. 1A to
F). The human T cells expressing CD4 (primary viral receptor)
and CCR5 (viral coreceptor) represent important HIV target
cells found in the FRT of BLT mice. When these data were
compared to human studies of T cells in cervicovaginal mucosa
and cervical epithelia, we found that BLT mice exhibit a higher
CD4 T cell proportion of total CD3 T cells than reported in
the human lower reproductive tract; however, the proportions
of CCR5-positive T cells in the FRT were essentially the same
between humans and BLT mice (21, 34, 40). Second, we de-
termined the systemic reconstitution with HIV-1 target cells by
measuring the levels of human cells in peripheral blood. Blood
analysis of all mice used in the testing of microbicides showed
that 52% (mean; standard deviation [SD] 17%; n  64) of all
circulating cells were human (Tables 2 to 5). Further analysis
showed that 83% (mean; SD, 7%; n  64) of circulating
human T cells expressed CD4 (Tables 2 to 5). The BLT mouse
blood CD4 T cell proportion is higher than normally seen in
humans but still within the range of what has been described
for healthy humans (2, 8, 36). These results demonstrate the
suitability of the utilized BLT mice to perform the in vivo
evaluation of topical microbicides to prevent vaginal HIV-1
transmission.
To date, CAPRISA 004 has provided the only successful
demonstration that a topical microbicide can prevent vaginal
HIV-1 transmission (1). Therefore, to validate the use of BLT
mice for the evaluation of topical inhibitors of vaginal HIV-1
transmission, we utilized the same study design as in the
CAPRISA 004 trial (Fig. 2), where study subjects were asked
to apply a 1% tenofovir product twice (once before and once
after sex with both applications occurring within a 24-h period)
(1). In our experiments, BLT mice received 1% tenofovir once
FIG. 1. The female reproductive tract of humanized BLT mice is efficiently repopulated with human HIV-1 target cells rendering them
susceptible to infection. (A) Flow cytometric analysis of cells from the FRT of a representative naive humanized BLT mouse demonstrates its
reconstitution with human CD4 and CD8 T cells. The gating strategy for flow cytometric analysis is as follows: live cells 3 human CD45 3
human CD3 3 human CD4 or CD8. (B) The box plot shows that the proportions of human T cells in the FRT are robust and reproducible in
BLT mice. (C) Human CD4 T cells from the FRT of the representative BLT mouse were further analyzed to demonstrate their surface expression
of the chemokine receptor CCR5 (left). The panel on the right shows fluorescence-minus-one staining control with isotype-matched fluorophore-
conjugated antibody to facilitate appropriate gating of the CCR5-expressing human CD4 T cells. (D) Box plot shows the levels of human CD4
CCR5 T cells in the FRT. (E) Human CD8 T cells from the FRT of the representative BLT mouse were further analyzed to demonstrate surface
expression of the chemokine receptor CCR5 (left). The panel on the right shows fluorescence-minus-one staining control with isotype-matched
fluorophore-conjugated antibody to facilitate appropriate gating of the CCR5-expressing human CD8 T cells. (F) Box plot shows the levels of
human CD8 CCR5 T cells in the FRT in BLT mice.
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before and once after HIV-1JR-CSF exposure according to the
clinical trial protocol. In the CAPRISA 004 study, a 39%
overall reduction in HIV incidence was observed, as deter-
mined by rapid tests and confirmed by viral load analysis (1). In
BLT mice, we observed 88% protection from vaginal HIV-1
transmission, as determined by plasma viral load analysis, and
protection from vaginal HIV transmission was confirmed by
the lack of detectable viral DNA in peripheral blood and
tissues (Fig. 3A to E and Table 2). In contrast, plasma viral
RNA and cell-associated viral DNA were readily detectable in
all infected control mice and the one breakthrough mouse
which received 1% tenofovir treatment (Fig. 3A to E; Table 2).
These results obtained using the CAPRISA 004 study design in
BLT mice demonstrate the ability of 1% tenofovir to reduce
vaginal HIV-1 infection in this model and strongly support the
use of this model for the evaluation of candidate topical mi-
crobicides for their ability to prevent HIV transmission.
Based on these encouraging results, we proceeded to eval-
uate the efficacy of six additional microbicide candidates to
prevent vaginal HIV-1 transmission in humanized BLT mice
(Table 1 and Fig. 4). Prior to selection for in vivo efficacy
evaluation here, each inhibitor was shown to efficiently inhibit
HIV in vitro (3, 5, 39, 43, 50, 52, 54, 56). Our experimental
approach for testing these six inhibitors was a single dose of the
product administered prior to exposure rather than the two
doses of drug administered within 24 h as used in CAPRISA
004 (1). This experimental design is based on the more stan-
dard single-dose administration prior to exposure (19, 23, 29,
35, 44, 47). This approach is simpler, more cost-effective than
multiple applications per sexual encounter and has been pos-
tulated to help increase adherence among women (51). For
these reasons this approach has been included as one arm in an
upcoming trial by the Microbicides Development Programme
(MDP 302) (51). Furthermore, the “single dose prior to or with
TABLE 2. Description of BLT mice used to evaluate the vaginal HIV-1 transmission prevention potential of 1% tenofovira
Treatment and
mouse no.
PB profile at exposure:b
No. of weeks followed
(exposure to harvest)












1 63 77 3 Neg (0/3) Neg (0/3) B, LI, LN, LU, O, S
2 51 72 6 Neg (0/6) Neg (0/6) B, LI, LN, LU, O, S
3 54 68 7 Neg (0/7) Neg (0/7) B, FRT, LI, LN, LU, O, S
4 37 73 7 Neg (0/7) Neg (0/7) B, FRT, LI, LN, LU, O, S
5 72 77 7 Neg (0/7) Neg (0/7) B, FRT, LI, LN, LU, O, S
6 62 88 7 Pos (5/7) Pos (5/7) B, FRT, LI, LN, LU, O
7 38 86 7 Neg (0/7) Neg (0/7) B, FRT, LI, LN, LU, O, S
8 64 77 7 Neg (0/7) Neg (0/7) B, LI, LN, LU, O, S
Control
9 55 83 7 Pos (3/3) Pos (3/3) LN, LU
10 58 89 9 Pos (4/4) Pos (3/4) B, LI, O, S
11 28 93 13 Neg (0/5) Neg (0/5) ND
12 29 89 13 Pos (5/5) Pos (3/5) B, LI, LU, O, S
Mean  SD 51%  4% 81%  2% 8  1
a Data shown represent analyses performed on all mice. Data for infected mice are shown in bold.
b PB, peripheral blood; hCD45, human CD45; hCD3, human CD3; hCD4, human CD4.
c For values in parentheses, the first number represents the number of positive results out of the second number, which represents the number of different time points
(total samples) tested. Neg, negative; Pos, positive.
d Reverse transcriptase real-time PCR limit of detection, 400 copies/ml.
e Real-time PCR limit of detection, 10 copies.
f B, bone marrow; FRT, female reproductive tract; LI, liver; LN, lymph nodes; LU, lung; O, thymic organoid; S, spleen; ND, not done.
FIG. 2. Experimental design for the validation of BLT mice for pre-
clinical efficacy evaluation of HIV prevention strategies. (A) CAPRISA
004 experimental design. The CAPRISA 004 trial design incorporated
a novel strategy for dosing referred to as BAT24 and was modeled on
the timing of nevirapine used to prevent mother-to-child HIV trans-
mission. BAT24 means that the study product (1% tenofovir or pla-
cebo) is applied within 12 h before and up to 12 h after vaginal
intercourse, but no more than 2 applications were to occur within a
24-h period. (B) Evaluation of 1% tenofovir in BLT mice using the
CAPRISA 004 experimental design. To validate BLT mice for the
evaluation of HIV prevention interventions, the application of 1%
tenofovir and the viral exposure were strictly performed according to
the BAT24 protocol as in the human trial. Note the significantly
shorter time frame for the BLT mouse experiments.
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each sexual encounter” protocol has been the most common
microbicide application protocol applied in clinical trials and
animal model studies (19, 23, 29, 35, 38, 44, 47, 50, 52). The six
additional candidate microbicides that we tested using this
experimental design represent a broad spectrum of inhibitors
with distinct mechanisms capable of blocking HIV infection at
several different steps of the viral replication cycle from preen-
try to postbudding (Table 1).
C52L is a sequence-modified C-peptide version of T-20 that
binds to the N-terminal heptad repeat of gp41 to block fusion
between the virion and the cell membranes (10, 50). C5A is an
amphipathic -helical peptide HIV inhibitor derived from the
hepatitis C virus NS5A anchor domain (5). C5A acts at preen-
try by disrupting the integrity of the viral membrane and the
mature viral core. PIE12-Trimer is a D-peptide that binds to a
conserved pocket on the surface of trimeric gp41. PIE12-
Trimer blocks the final stages of the fusion process between the
virion and cell membranes (54). TC247 is a thioester com-
pound zinc finger inhibitor that ejects zinc ions from the two
HIV nucleocapsid zinc finger loops (32). TC247 has been
shown to affect HIV at multiple stages of replication but is







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FIG. 3. Effective protection from vaginal HIV-1 infection by topi-
cal 1% tenofovir. Using the experimental protocol shown in Fig. 1B
that reproduces CAPRISA 004, BLT mice were exposed vaginally to
HIV with (n  8) or without (n  4) tenofovir treatments. Seven of 8
BLT mice treated topically with 1% tenofovir exhibited a complete
absence of plasma viral RNA (A), PBMC-associated viral DNA (B),
and cell-associated viral DNA in multiple tissues (C), indicating that
they were protected from vaginal HIV-1 transmission. Three of 4
control BLT mice were infected as determined by the presence of
plasma viral RNA (D), PBMC-associated viral DNA (E), and cell-
associated viral DNA in multiple tissues (C). Dashed lines represent
the limits of detection for the respective assays.
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cessing and maturation of virions, rendering progeny virions
noninfectious and thus preventing viral spread. NSC23766 is a
small molecular inhibitor of Rac1-guanine nucleotide ex-
change factors (GEFs) TrioN and Tiam1. NSC23766 prevents
viral entry from the inside-out by interfering with the structural
modifications that occur within the cell during fusion (16, 39).
The combination of the reverse transcriptase inhibitors FTC-
TDF, the inhibitors present in Truvada (3, 43), targets posten-
try viral DNA synthesis.
Following the vaginal administration of each inhibitor, treated
BLT mice were challenged vaginally with the same dose of
HIV-1JR-CSF as described above for tenofovir. Peripheral
blood from BLT mice was sampled longitudinally following
viral exposure for evidence of infection (Fig. 5). The presence
of HIV-1 plasma antigenemia, PBMC-associated viral DNA,
or plasma viral RNA in exposed mice was considered evidence
of transmission. In the absence of HIV inhibitor, transmission
was documented in 10/12 control mice (Fig. 5A to C).
Differential levels of protection from HIV transmission were
noted among the six inhibitors. Specifically, the Rac inhibitor
NSC23766 did not protect any BLT mice (4/4 pretreated BLT
mice were infected). The zinc finger inhibitor TC247 protected
4/7 BLT mice. The combination of FTC-TDF protected 8/9
BLT mice from infection (Fig. 5D to F). Remarkably, com-
plete protection was observed with C52L (0/7), C5A (0/8), or
PIE12-Trimer (0/5) (Fig. 5G to I). Protection from vaginal
HIV-1 infection by C52L, C5A, PIE12-Trimer, FTC-TDF, and
TC247 was verified by three additional criteria: viral rescue by
coculture with allogeneic PBMC, real-time PCR analysis for
the presence of viral DNA in tissues, and in situ hybridization
analysis for the presence of productively infected cells. Using
these techniques, there was no evidence of infection in any of
the inhibitor-protected mice. In contrast, clear evidence of
HIV-1 infection was obtained in the tissues analyzed from
control or breakthrough animals (Tables 3 to 5).
Importantly, protection of BLT mice pretreated with teno-
fovir, C52L, C5A, PIE12-Trimer, FTC-TDF, and TC247 was
not attributable to a lack of human reconstitution within the
FRT. Flow cytometry analysis of the FRT confirmed the pres-
ence of human CD4 T cells in protected animals at levels that
were comparable to controls (naive [n  4] versus protected
[n  6]; Mann-Whitney test, P  0.76) (Fig. 1B and 6A).
Furthermore, in addition to human CD3 T cells, the presence
of CD11c dendritic cells and CD68 monocyte/macrophages
in the FRT of BLT mice was confirmed by immunofluores-
cence staining (Fig. 6B). Therefore, lack of HIV-1 infection in
the mice treated with these inhibitors was not due to the
absence of target cells in the FRT. Rather, the lack of vaginal
HIV-1 transmission is attributed to the protective effect pro-
vided by the tested inhibitors.
Based on the extensive molecular and cellular analyses pre-
sented above, we formulated the following summary (Fig. 7):
the Rac inhibitor (NSC23766; n  4) did not protect any mice
from HIV infection. The zinc finger inhibitor (TC247; n  7)
protected 57% of treated animals. The postentry reverse trans-
criptase inhibitor combination (FTC-TDF; n  9) and two
applications of a single reverse transcriptase inhibitor (1%
tenofovir; n  8) each similarly protected 88% of treated
animals. Each of the three peptide inhibitors (C52L [n  7],
C5A [n  8], and PIE12-Trimer [n  5]) protected 100% of
treated BLT mice from vaginal HIV-1 transmission. The
protection afforded by these last five inhibitors, when each
was independently compared to the no-inhibitor controls,
was significant as determined by log rank (Mantel-Cox)
analysis (Fig. 7).
DISCUSSION
The availability of a safe, inexpensive, and effective micro-
bicide would have the potential to help stop the spread of HIV
(9, 30). Animal models are critical to the development, testing,
and implementation of novel and effective microbicides. Re-
cently published results from the landmark iPrEx trial demon-
strated that systemic FTC and TDF reduced the incidence of
rectal HIV transmission by 44% (18). Previous studies from
our laboratory demonstrated that this combination of drugs
offered a 100% protection from rectal HIV transmission in
humanized BLT mice (12). Superficially, these numbers seem
to be high compared to those from the overall efficacy dem-
onstrated in the iPrEx trial using the same drugs. However,
these numbers are in concordance with the greater than 90%
FIG. 4. Experimental design for the evaluation of candidate micro-
bicides for their ability to prevent vaginal HIV transmission in human-
ized BLT mice. (A) Conventional trial design for evaluation in humans
and NHPs. The conventional clinical trial design and NHP topical
inhibitor protocol are to apply the inhibitor between 60 min prior to
intercourse and immediately concordant with intercourse. Microbi-
cides Development Program (MDP) trial 302 has a planned arm uti-
lizing a single application of the inhibitor, as has been used in numer-
ous other trial designs (51). This trial design is considered to be
simpler, more cost efficient, and easier to adhere to than BAT24
(CAPRISA 004 trial design) or daily (VOICE trial design) inhibitor
applications (51). (B) Experimental design for evaluation in BLT mice.
The experimental protocol for evaluating C52L, C5A, PIE12-Trimer,
FTC-TDF, TC247, and NSC23766 was designed to closely replicate the
conventional approach for microbicide efficacy determinations shown
in panel A.
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reduction in risk of HIV transmission observed among subjects
with detectable study drug levels in this same trial (18). Even
though similar data are not yet available regarding the preven-
tion of vaginal HIV transmission in humans, preclinical data
generated in humanized BLT mice also showed that systemic
administration of FTC and TDF results in a high level of
protection from vaginal HIV infection (11).
In the manuscript, we further validated the humanized
BLT mouse model for the evaluation of HIV preventive
approaches by reproducing the experimental approach used
in the CAPRISA 004 trial using tenofovir as a topical micro-
bicide. In the CAPRISA 004 trial, participants were instructed
to apply a 1% tenofovir gel twice within a 24-h period, once
before and once after sex (1). This resulted in an overall 39%
reduction in incidence of vaginal HIV transmission, and self-
reported “high adherers” (80%) experienced a 54% reduc-
tion in incidence of HIV infection. In BLT mice the same
protocol was implemented, resulting in a higher level of partial
protection than seen in the human trial. In BLT mice 1%
tenofovir treatment resulted in 88% protection from vaginal
HIV infection (Fig. 7). It is interesting that a single vaginal
application of 1% tenofovir to nonhuman primates also re-
sulted in higher protection (38). The higher level of protection
in animal models could be the result of confounding factors in
FIG. 5. Peripheral blood analyses show differential protection from vaginal HIV transmission by the indicated HIV inhibitors when applied
topically prior to exposure. (A to C) Ten of 12 control BLT mice were positive for plasma antigenemia, for PBMC viral DNA, and for plasma viral
RNA. (D) All mice treated with the Rac inhibitor NSC23766 were positive for viral antigenemia. Four of seven mice treated with the zinc finger
inhibitor TC247 were consistently negative for plasma viral antigenemia. All nine BLT mice treated with the reverse transcriptase inhibitor
combination FTC-TDF were negative for p24 in plasma. (E) Four of seven mice treated with TC247 and all nine mice treated with FTC-TDF were
consistently negative for PBMC viral DNA. PBMC from all mice treated with NSC23766 were positive for viral DNA. (F) Four of seven mice
treated with TC247 and eight of nine mice treated with FTC-TDF were consistently negative for plasma viral RNA. In the FTC-TDF group there
was breakthrough infection in one mouse (mouse 33). Once confirmed positive by two consecutive viral load analyses, this mouse was harvested
for analysis at a point analogous to Fiebig stage I of primary HIV infection in humans (15), i.e., viral RNA positive (F) but plasma antigenemia
and viral DNA negative (D and E). Subsequent tissue DNA real-time PCR and in situ hybridization analysis confirmed this breakthrough infection
despite topical FTC-TDF treatment (Table 4). (G to I) Plasma antigenemia, PBMC viral DNA, and plasma viral RNA were absent in all samples
analyzed from mice treated with C52L, C5A, and PIE12-Trimer. Dashed lines represent the limits of detection for the respective assays.
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human trials that are not present in the controlled conditions
used to perform experiments in these systems. Specifically,
whereas compliance in BLT mice is not an issue, compliance
with the inhibitor application protocol in humans was a signif-
icant problem. Whereas in BLT mice application of the inhib-
itor precludes loss of the product, this might not be the case in
humans, reducing the effective concentration at the time of
exposure. Whereas in BLT mice HIV exposure and transmis-
sion are highly reproducible, the number of viral exposures,
timing of viral exposures relative to inhibitor dosing, etc., are
highly variable in humans. All these and other intangibles
complicating the human experiments do not diminish the use-
fulness of BLT mice for rapidly screening this and other HIV
prevention interventions. Also, further validation of the BLT
model for the evaluation of HIV prevention strategies comes
from our previous study where the humanized BLT mouse
demonstrated similar results to the iPrEx trial (12, 18).
After validating BLT mice for preclinical efficacy evaluations
of topical microbicides to prevent vaginal HIV transmission,
we proceeded to screen six additional microbicide candidates
for in vivo efficacy. These inhibitors target HIV at different
stages of the replication cycle (Table 1). The result of our
screen was that four of the microbicide candidates tested can
efficiently prevent vaginal HIV transmission in vivo: C52L,
C5A, PIE12-Trimer, and FTC-TDF (Fig. 7). Two other can-
didate microbicides (TC247 and NSC23766) offered partial or
no protection from HIV infection (Fig. 7). This initial screen
identified compounds that effectively inhibit vaginal HIV
transmission. However, prior to the clinical implementation of
these inhibitors, more in vivo experiments with these com-
FIG. 6. Protection in inhibitor-pretreated BLT mice was not attributable to a lack of human reconstitution within the FRT. (A) Human CD4
and CD8 T cell levels in the FRT of mice protected by vaginally applied HIV inhibitors (1% tenofovir, mouse 3; C52L, mouse 17; C5A, mouse
23; PIE12-Trimer, mouse 28; FTC-TDF, mouse 36; and TC247, mouse 48) were determined to be similar to those observed in the FRT of normal
BLT mice (Fig. 1A and B). In contrast, vaginal HIV-1 transmission results in a dramatic loss of human CD4 T cells in the FRT of infected control
BLT mice (right panel; mouse 54). Note that two antibody panels were utilized for this analysis, and this accounts for the small mean fluorescence
intensity differences (see Materials and Methods for details). The gating strategy for flow cytometric analysis was as follows: live cells 3 human
CD453 human CD33 human CD4 or CD8. (B) Immunofluorescence analysis confirms the presence of human T cells (CD3; red), dendritic cells
(CD11c; green in left panels), and monocyte/macrophages (CD68; green in right panels) in a C5A-protected BLT mouse FRT (mouse 20). Human
hematopoietic cells in the FRT were not observed in nonhumanized controls. Nuclei are stained in blue (bar, 100 mm).
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pounds are warranted. For example, cohorts of BLT mice can
be treated with reduced doses of these inhibitors to determine
the minimum effective doses. In addition, the protocols gov-
erning the timing of inhibitor and virus delivery can be modi-
fied to determine the maximum and minimum time pre- and
postexposure at which the inhibitors retain their ability to
prevent vaginal HIV transmission. The results of these analy-
ses would directly inform the process for implementing these
inhibitors clinically.
A lack of validated model systems for in vivo microbicide
efficacy evaluation has made it difficult to rapidly bring novel
microbicide candidates forward for evaluation in humans. Un-
til recently, nonhuman primate (NHP) studies have served as
the only model system for in vivo preclinical testing of HIV
prevention approaches through the use of simian immunode-
ficiency virus (SIV) and SHIV (48). An example of the suc-
cessful use of an NHP model in HIV prevention is the study of
Parikh, et al., which used SHIVSF162P3 and pig-tailed macaques
to predict that tenofovir gel could block vaginal HIV transmis-
sion as was subsequently determined in the CAPRISA 004
clinical trial (1, 38). Yet because many new-generation micro-
bicides being considered contain antiretrovirals that often ex-
hibit exquisite specificity for HIV, multiple SIV/SHIV ma-
caque models need to be developed for efficacy testing in vivo
(20, 27, 28, 38, 46, 50, 52). Furthermore, within different NHP
models there are differences in viral (i.e., HIV versus SHIV
envelope variable region 3) and host (i.e., human versus ma-
caque CCR5) sequences, resulting in distinctions that preclude
the use of certain HIV-specific inhibitors and can confound the
interpretation of the data obtained (4, 33, 42, 49). These fac-
tors together with the expense of NHP testing and the limited
availability of female animals have severely limited their broad
utilization in the evaluation of novel HIV prevention interven-
tions. In contrast, the humanized BLT mouse model repro-
duces key aspects of the human condition. Specifically, BLT
mice have the distinctive advantage of permitting in vivo eval-
uation of microbicide candidates using human primary isolates
of HIV that interact with human primary cells expressing nor-
mal levels of human receptors and coreceptors. Here, we pres-
ent critical experimental results using topical 1% tenofovir that
validate the use of BLT mice for the in vivo evaluation of novel
HIV microbicide candidates.
Four of the seven inhibitors utilized for our studies also have
been tested in NHP (TC247, C52L, tenofovir, and FTC-TDF).
This represents the first opportunity to compare results from
NHP studies to those obtained in the BLT model and in the
case of tenofovir with those from the human clinical trial. The
comparison between the two in vivo preclinical models is fur-
ther enhanced due to the similar experimental designs between
the NHP and BLT studies where a single dose of the inhibitor
preceded the viral exposure in each case (38, 50, 52). Despite
the higher drug dosing used for macaques (37.6 mM versus 0.5
mM), TC247 offered similar protection in both models (5 of 6
macaques and 4 of 7 BLT mice) (52). C52L (500 M) pro-
tected 7 of 7 BLT mice. In macaques, C52L protected 7/15
animals when used at a range of 50 to 1,500 M (50). FTC-
TDF also provided similar protection in the two systems (6/6
macaques protected and 8/9 BLT mice protected) (38). A
single dose of tenofovir applied 30 min before exposure in
pig-tailed macaques protected 6/6 animals, and tenofovir ad-
ministered twice (before and after exposure) as done in the
CAPRISA 004 trial protected 7/8 humanized BLT mice (Fig.
7) (1, 38). The collective data accumulated in two different
animal models of HIV transmission to evaluate HIV preven-
tion strategies demonstrate their potential predictive value to
humans. Together, these results demonstrate that multiple mi-
crobicide candidates not currently included in HIV therapeutic
regimens have the potential to prevent vaginal HIV transmis-
sion in humans.
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